Daniele Sommacale
Prof Daniele Sommacale is an expert in Surgery at Assistance Publique - Hôpitaux de Paris (France). Daniele Sommacale has authored 237 publications, the most recent in 2026, and is an investigator in 6 clinical trials, 1 of them ongoing. SLR score: 565 (community average: 125). How the SLR is computed.
LeadR Profile
Surgery
Subspecialties: Hepatology - Oncology - Gastroenterology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2000 - 2026
Number : 237
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Does Surgical Approach Influence Benchmark Attainment in Intrahepatic Cholangiocarcinoma? PMID 42496491 — mortality, lymph node excision, neoplasms, liver, general surgery, cholangiocarcinoma, intrahepatic cholangiocarcinoma | World J Surg | 2026 | 0 |
| FRIES score: predicting conversion in robotic liver surgery. PMID 42258771 — minimally invasive surgical procedures, surgical procedures, operative, liver, postoperative complications | BJS Open | 2026 | 0 |
| Utility of the Iwate Difficulty Scoring System for the Stratification of Laparoscopic Right Hepatectomies: An International Multicenter Study. PMID 42130324 — liver diseases, hepatectomy, morbidity | J Hepatobiliary Pancreat Sci | 2026 | 0 |
| ASO Visual Abstract: Enhanced Recovery After Liver Surgery: Does Compliance Impact Survival? PMID 42002717 — recycling, liver | Ann Surg Oncol | 2026 | 0 |
| Enhanced Recovery After Liver Surgery: Does Compliance Impact Survival? PMID 41926013 — mortality, recycling, liver | Ann Surg Oncol | 2026 | 1 |
Clinical Studies 6
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 9
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| JAK1 inhibitor treatment of inflammatory liver adenomas 2023-505278-13-00 — estrogens, neoplasms, contraception, liver, adenoma, liver cell, histology, adenoma, therapeutics, male, women | Phase 2 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map